• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

直接口服抗凝剂对 Ceveron TGA 凝血酶生成的影响。

Influence of direct oral anticoagulants on thrombin generation on Ceveron TGA.

机构信息

Division of Hemostaseology, Medical Department I, University Hospital Leipzig, Leipzig, Germany.

MVZ Limbach Magdeburg, Lab Dr. Franke, Bönigk and Colleagues, Center of Coagulation Disorders and Vascular Diseases, Magdeburg, Germany.

出版信息

Int J Lab Hematol. 2022 Feb;44(1):193-201. doi: 10.1111/ijlh.13721. Epub 2021 Sep 29.

DOI:10.1111/ijlh.13721
PMID:34585540
Abstract

INTRODUCTION

Monitoring of direct oral anticoagulants (DOACs) with calibrated anti-Xa assay is limited by the high intra- and interindividual variations of the test results. Thrombin generation (TG) is a global hemostatic assay that reflects the patient´s individual coagulation status. The aim of this study was to investigate the influence of DOACs on TG measured with a fully automated assay system.

METHODS

All consecutive patients under apixaban and rivaroxaban coming to the outpatient coagulation center MVZ Limbach, Magdeburg, Germany between October 2017 and April 2020 were included. DOAC plasma levels were correlated with TG assessed using the fully automated Ceveron TG analyzer.

RESULTS

A total of 703 rivaroxaban and 252 apixaban containing plasma samples were included. There was a significant correlation between DOAC plasma levels and all TG parameters except for lag time regarding apixaban. Time to peak and peak thrombin followed an exponential regression curve, while this was linear for the endogenous thrombin potential (ETP). Apixaban showed a lower correlation coefficient for all TG parameters compared with rivaroxaban, and thrombin generation was less influenced by apixaban than rivaroxaban at plasma levels >100 ng/ml. The sensitivity and negative predictive value of normal TG parameters for the prediction of DOAC plasma levels <30 ng/ml was >85%.

CONCLUSION

The present data show a moderate predominantly nonlinear correlation between TG parameters and plasma levels of apixaban and rivaroxaban. Rivaroxaban has a stronger effect on TG than apixaban.

摘要

简介

使用校准的抗-Xa 测定法监测直接口服抗凝剂(DOAC)受到测试结果个体内和个体间高度变化的限制。血栓生成(TG)是一种反映患者个体凝血状态的整体止血测定法。本研究旨在探讨 DOAC 对使用全自动测定系统测量的 TG 的影响。

方法

纳入 2017 年 10 月至 2020 年 4 月期间在德国马格德堡 MVZ Limbach 门诊凝血中心就诊的所有连续接受阿哌沙班和利伐沙班治疗的患者。将 DOAC 血浆水平与使用全自动 Ceveron TG 分析仪评估的 TG 相关联。

结果

共纳入 703 例利伐沙班和 252 例阿哌沙班含血浆样本。除阿哌沙班的滞后时间外,DOAC 血浆水平与所有 TG 参数均呈显著相关。达峰时间和最大血栓生成量呈指数回归曲线,而内源性血栓生成潜力(ETP)则呈线性关系。与利伐沙班相比,阿哌沙班的所有 TG 参数的相关系数均较低,并且在血浆水平>100ng/ml 时,阿哌沙班对血栓生成的影响小于利伐沙班。正常 TG 参数预测 DOAC 血浆水平<30ng/ml 的敏感性和阴性预测值>85%。

结论

本研究数据表明,阿哌沙班和利伐沙班的 TG 参数与血浆水平之间存在中度且主要是非线性的相关性。利伐沙班对 TG 的影响大于阿哌沙班。

相似文献

1
Influence of direct oral anticoagulants on thrombin generation on Ceveron TGA.直接口服抗凝剂对 Ceveron TGA 凝血酶生成的影响。
Int J Lab Hematol. 2022 Feb;44(1):193-201. doi: 10.1111/ijlh.13721. Epub 2021 Sep 29.
2
Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.直接口服抗凝剂特定凝血检测的局限性:批判性分析。
J Am Heart Assoc. 2018 Oct 2;7(19):e009807. doi: 10.1161/JAHA.118.009807.
3
Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement.阿哌沙班和利伐沙班预防血栓形成剂量与全髋关节置换术相关的凝血及凝血酶生成的影响
J Thromb Thrombolysis. 2017 May;43(4):562-569. doi: 10.1007/s11239-017-1492-2.
4
Plasma levels do not predict thrombin generation in patients taking direct oral anticoagulants.直接口服抗凝剂治疗患者的血浆水平不能预测凝血酶生成。
Int J Lab Hematol. 2021 Dec;43(6):1539-1548. doi: 10.1111/ijlh.13618. Epub 2021 Jun 7.
5
Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.在接受直接口服抗凝剂治疗的患者中,凝血筛选试验与特定检测方法的可比性较差:一项多中心/多平台研究的结果。
J Thromb Haemost. 2016 Nov;14(11):2194-2201. doi: 10.1111/jth.13486. Epub 2016 Oct 15.
6
Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.每日一次利伐沙班和每日两次阿哌沙班的药代动力学和药效学分离:一项随机交叉研究。
J Thromb Haemost. 2017 Oct;15(10):2017-2028. doi: 10.1111/jth.13801. Epub 2017 Sep 14.
7
Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.高危心房颤动患者使用直接口服抗凝剂时药物水平低且血栓并发症风险高。
J Thromb Haemost. 2018 May;16(5):842-848. doi: 10.1111/jth.14001. Epub 2018 Apr 17.
8
Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.采用低分子肝素校准的抗因子 Xa 测定法来评估阿哌沙班和利伐沙班的浓度。
Int J Lab Hematol. 2022 Feb;44(1):163-167. doi: 10.1111/ijlh.13692. Epub 2021 Sep 15.
9
Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients.探讨 Xa 因子抑制剂对旋转血栓弹性描记术的影响:出血患者的病例系列。
J Thromb Thrombolysis. 2019 Feb;47(2):272-279. doi: 10.1007/s11239-018-1785-0.
10
Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.服用阿哌沙班或利伐沙班治疗房颤或静脉血栓栓塞的退伍军人的出血率。
J Thromb Thrombolysis. 2019 Feb;47(2):280-286. doi: 10.1007/s11239-018-1770-7.

引用本文的文献

1
Fibrinography and thrombography (thrombodynamics-4D) in atrial fibrillation assessment of direct oral anticoagulants in geriatrics patients aged 80 years and older receiving direct oral anticoagulant therapy.纤维蛋白成像和血栓成像(血栓动力学-4D)在80岁及以上接受直接口服抗凝剂治疗的老年房颤患者直接口服抗凝剂评估中的应用
Res Pract Thromb Haemost. 2025 Jul 15;9(5):102969. doi: 10.1016/j.rpth.2025.102969. eCollection 2025 Jul.
2
Thrombin Generation Assay to Support Hematologists in the Era of New Hemophilia Therapies.凝血酶生成试验助力血液科医生应对新型血友病疗法时代。
Int J Lab Hematol. 2025 Apr;47(2):212-220. doi: 10.1111/ijlh.14406. Epub 2024 Dec 11.
3
Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases.
用于出血和血栓性疾病个性化治疗的凝血酶生成检测。
Front Cardiovasc Med. 2022 Nov 10;9:1033416. doi: 10.3389/fcvm.2022.1033416. eCollection 2022.